Navigation Links
Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Date:6/12/2008

Program Supports Development of Strong Scientific Capacity in Latin America

WASHINGTON, June 12 /PRNewswire-USNewswire/ -- The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today that 10 promising biomedical scientists have been named 2008 Pew Latin American Fellows in the Biomedical Sciences. Funded by Pew through a grant to UCSF, the highly competitive fellowship program offers talented young Latin American scientists $60,000 for a two-year training period. The award is administered by the sponsoring U.S. institution, which supplements the stipend with at least $5,000 a year and also provides medical benefits for the fellow. Following the two year fellowship, the Program will issue an additional $35,000 award to the sponsoring institution to purchase equipment and supplies for the fellow to establish a laboratory in his or her home country.

"Pew's Latin American Fellows Program gives these exemplary scientists the opportunity to further their knowledge, and it promotes exchange and collaboration between researchers in the United States and Latin America," said Rebecca W. Rimel, President and Chief Executive Officer of The Pew Charitable Trusts.

The Pew Latin American Fellows Program in the Biomedical Sciences was launched in 1991 to help develop a cadre of highly trained Latin American scientists who could stimulate and contribute to the growth of quality biomedical science and foster collaboration between scientists in Latin America and the U.S. Since 1991, the Trusts has invested more than $11 million to fund more than 150 fellows, close to 80 percent of whom have returned to their home countries. Applicants from all Central and South American countries are invited to apply, and selection is made by a distinguished national advisory committee chaired by Dr. Torsten N. Wiesel, president emeritus of Rockefeller University and a 1981 Nobel laureate in physiology or medicine.

The 2008 Pe
'/>"/>

SOURCE Pew Charitable Trusts
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
3. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
4. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
5. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
6. White Paper Details New Techniques for Isolating, Identifying Anaerobic Bacteria and Organisms
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
8. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
11. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ -...d & Drug Administration (SFDA) has approved th...ts oral insulin project,(Nodlin), an innovative in...oval allows Biolaxy to initiate its first phase I ...characteristic of high blood glucose and poor,meta...
(Date:11/24/2009)... The FBI recently approved the Pr...es participating in or generating DNA records for ... Madison, WI USA (PRWEB) -- The FBI recentl...m for use by laboratories participating in, or ge...ystem (NDIS). NDIS currently contains more than se...
(Date:11/24/2009)..., TSX VENTURE: HTL , TORONTO, Nov. 24 /PRN...HTL), formerly Calotto Capital Inc., a leading pro...r the stem cell research and fertility clinic mark...lts for the third quarter ended September 30, 2009...$1.46 million compared with $1.43 million in Q3 20...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-First...A ) announced today that the company is schedule...th Care Conference on December 1, 2009 at 11:30 a....w York Palace Hotel in New York City. Jack Lief, A...cheduled to provide an overview of the company, in...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...ANCOUVER and SAN DIEGO, Jan. 31 /PRNewswire-FirstC...ical-stage developer of drugs for infectious,disea...py arm to its,currently enrolling Phase II viral k...nt-naive patients. The protocol amendment to this ... Review Board (IRB) approvals. The,purpose of this...
...oundation Continues Research Initiatives in Search... for Paralysis, SHORT HILLS, N.J., Jan. 31 The...ch is dedicated to curing spinal cord injury by,fu...y of life for people,living with paralysis through... it has awarded $1,996,745 million to 16 laborator...
...ILLBROOK, N.Y., Jan. 31 Mr. Donald Fresne, Chairm...he company has recently,obtained from Harvard Univ...ts that cover certain technologies related to canc...chnologies, which were developed jointly,by scient...and the,Department of Biological Chemistry and Mol...
Other Biology Technology:MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 2MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 3MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 4MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 5MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study 6Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
(Date:11/25/2009)...BER 25, 2009 Soil is the linchpin of the environm...meet. Despite that, many students see soil as "jus... Soil science educators are challenged with the ta...e critical importance of soil in the environment. ...arth science teachers at University of Nebraska-Li...
(Date:11/24/2009)...ears it has been prescribed by traditional healers...ches and stomach pain to fever and flu. , Now for...ty have been able to scientifically prove the pain...se known as Brazilian mint. , Testing this ancien...earcher Graciela Rocha was able to show that when ...
(Date:11/24/2009)...eakened and flabby arteries from collapsing have b...stents are no longer needed -- once the arteries a...ly, doctors had no choice but to leave them in pla...ity,s Department of Biomedical Engineering has dev...rries drugs where they,re needed, then dissolves. ...
Breaking Biology News(10 mins):It's not just dirt! 2Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 1Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 2Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 3Final 12 Month Clinical Data from 5 000 Patients in Worldwide e HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich 14218 4Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 1Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 2Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 3Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 4Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 5Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 6Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 7Natural Alternatives International Inc Announces Fiscal 2009 Q4 and Full Year Results 58089 8MedCath Names Art Parker Executive Vice President and Chief Financial Officer 58084 1MedCath Names Art Parker Executive Vice President and Chief Financial Officer 58084 2
...r eye diseases and leading causes of blindnessage-...thycan be reversed or even prevented by drugs that...esearchers at the University of Utah School of Med...d in a new study. , Damage from both diseases was...o4, was activated in mice models that simulate age...
...oneers in small RNA research--Victor Ambros, Gary ...recent discoveries at a special half-day symposium...0 p.m., Wednesday, April 16, in the Gore Recital H...nt will be held in their honor, as the 2008 winner...dal in Life Science. , UD,s symposium is part of ...
...nderstand how nitrogen accumulates in large rivers...Walter Dodds looked at small streams flowing close...sas State University, didn,t have to look any fart... Creek at K-State was one of nine small waterways ... nitrogen is removed from streams. With a grant fr...
Other Biology News:Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 2Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice 3Pioneers in small RNA research to present at UD symposium, April 16 2Pioneers in small RNA research to present at UD symposium, April 16 3Research team finds that microorganisms filter nitrogen from small streams 2
...ptimised for SYBR Green I assays and contain all t...R, with the exception of template and primers. The... active SYBR Green I dye and Thermo-Start DNA Poly...hat enables detection of low copy number targets.,...
... all-in-one rotator/rocker with a multi-action pla... rotating, rocking/shaking, rotating/rocking, rol...mbination of all these actions. The precision-eng... Genie consists of a two-sided, stainless steel pl...
...ion Kit, Plasmid is designed for use with high-yie...No. 3 186 148, 3 186 156, 3 335 461). This kit pro... N-terminal AviTag peptide sequence. The expressed... E. coli biotin protein ligase (BirA, E.C. 6.3.4.1...
... RFC1 Immunogen Recombinant protein correspondin... expressed in E. coli. Reactivity / Specificity ... tested in other species. This antibody recognizes... Replication factor C is a multisubunit, DNA polym...
Biology Products: